A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE)
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE)
Authors
Keywords
Pneumococcal vaccine, Safety, Immunogenicity
Journal
VACCINE
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-09-08
DOI
10.1016/j.vaccine.2021.08.049
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and Effectiveness of a 23-Valent Polysaccharide Vaccine Against Invasive and Non-Invasive Pneumococcal Disease and Related Outcomes: A Review of Available Evidence
- (2021) Michael S. Niederman et al. Expert Review of Vaccines
- Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age
- (2020) Donald Hurley et al. CLINICAL INFECTIOUS DISEASES
- A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants
- (2020) Heather L. Platt et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Optimization and validation of a microcolony multiplexed opsonophagocytic killing assay for 15 pneumococcal serotypes
- (2020) Katrina M Nolan et al. Bioanalysis
- Enhanced antipneumococcal antibody electrochemiluminescence assay: validation and bridging to the WHO reference ELISA
- (2020) Katrina M Nolan et al. Bioanalysis
- Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults
- (2019) Helen L. Stacey et al. Human Vaccines & Immunotherapeutics
- Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013–18
- (2019) Harry Pick et al. THORAX
- Increased carriage of non-vaccine serotypes with low invasive disease potential four years after switching to the 10-valent pneumococcal conjugate vaccine in The Netherlands
- (2018) Marloes Vissers et al. PLoS One
- Serotype distribution of invasive Streptococcus pneumoniae in adults 65 years of age and over after the introduction of childhood 13-valent pneumococcal conjugate vaccination programs in Canada, 2010–2016
- (2018) Walter H.B. Demczuk et al. VACCINE
- Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age
- (2018) Susan J. Ermlich et al. VACCINE
- Vaccines for the elderly: current use and future challenges
- (2018) Birgit Weinberger Immunity & Ageing
- Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15
- (2018) Brian Wahl et al. Lancet Global Health
- Impact of 13-pneumococcal conjugate vaccine among adults: a systematic review and meta-analysis
- (2018) Nirma Khatri Vadlamudi et al. CLINICAL INFECTIOUS DISEASES
- Vaccination in the elderly: The challenge of immune changes with aging
- (2018) Annalisa Ciabattini et al. SEMINARS IN IMMUNOLOGY
- Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
- (2018) James T. Peterson et al. Human Vaccines & Immunotherapeutics
- Burden of vaccine-preventable pneumococcal disease in hospitalized adults: A Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) network study
- (2017) Jason J. LeBlanc et al. VACCINE
- Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis
- (2017) Gerhard Falkenhorst et al. PLoS One
- Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden
- (2016) Ilias Galanis et al. EUROPEAN RESPIRATORY JOURNAL
- Serotype 3 Remains the Leading Cause of Invasive Pneumococcal Disease in Adults in Portugal (2012–2014) Despite Continued Reductions in Other 13-Valent Conjugate Vaccine Serotypes
- (2016) Andreia N. Horácio et al. Frontiers in Microbiology
- Redefining risk categories for pneumococcal disease in adults: critical analysis of the evidence
- (2015) Daniel Curcio et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study
- (2015) Pauline A Waight et al. LANCET INFECTIOUS DISEASES
- Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance
- (2015) Matthew R Moore et al. LANCET INFECTIOUS DISEASES
- Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults
- (2015) Marc J.M. Bonten et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults
- (2014) John D. Grabenstein et al. VACCINE
- Safety and tolerability of 13-valent pneumococcal conjugate vaccine in the elderly
- (2014) Paolo Durando et al. Human Vaccines & Immunotherapeutics
- Pneumococcal infection in adults: burden of disease
- (2013) J.J.C. Drijkoningen et al. CLINICAL MICROBIOLOGY AND INFECTION
- Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: Review of evidence on indirect effects
- (2013) Stephanie M. Davis et al. VACCINE
- Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
- (2013) Lisa A. Jackson et al. VACCINE
- Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults
- (2013) Lisa A. Jackson et al. VACCINE
- Protein carriers of conjugate vaccines: Characteristics, development and clinical trials
- (2013) Michael E Pichichero Human Vaccines & Immunotherapeutics
- Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
- (2011) Michael T Osterholm et al. LANCET INFECTIOUS DISEASES
- Healthcare utilization and cost of pneumococcal disease in the United States
- (2011) Susan S. Huang et al. VACCINE
- Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease
- (2010) Inci Yildirim et al. VACCINE
- Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: A matched case–control study
- (2009) Angel Vila-Corcoles et al. VACCINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now